Chemcon (CHEMCON) Q2 FY27 Profit Slumps 31% as Q1 Margin Gains Reverse
Chemcon's Q2 profit fell sharply despite steady revenue, as a favorable inventory swing from the prior quarter normalized and costs rose.
Chemcon Speciality Chemicals posted a 22% yearly revenue rise in Q2 FY27, but profit dropped 31% sequentially. The reversal followed a one-off inventory benefit that had boosted margins in Q1.
For a specialty chemicals maker like Chemcon, the story is often told in margins—the delicate balance between its unique product pricing and volatile input costs. The September quarter delivered a clear lesson in that volatility, as a sharp yearly sales gain was overshadowed by a steep quarterly profit drop.
Revenue for Q2 FY27 stood at ₹65.45 crore, up 21.9% from a year ago but essentially flat from the June quarter. Profit, however, fell 31.4% sequentially to ₹7.52 crore. The net profit margin compressed to 11.5%, down 500 basis points from the 16.5% recorded in Q1.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ2 FY27 | PreviousQ1 FY27 | Same quarter LYQ2 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 65.45YoY +22% | 66.49 | 53.71 |
| Profit (₹ Cr) | 7.52YoY +31% | 10.96 | 5.75 |
| Net Profit Margin | 11.5%YoY +7.5% | 16.5% | 10.7% |
Why the Margin Spike Faded
The profit decline was primarily a reversal of a temporary cost advantage. According to a Stockwatch.live analysis, Q1's standout margin was flattered by an unusually large inventory build, which reduced the reported cost of goods sold. This working-capital swing normalized in Q2, pulling profitability back toward its underlying trend.
This pattern suggests the business is in transition, where operational improvements are being offset by volume or product-mix challenges, as noted by StockFin.ai. The company's niche in pharmaceutical intermediates like HMDS and CMIC provides pricing power, but quarterly earnings remain susceptible to these operational swings.
A Steady Hand, But Murky Road Ahead
Management has not provided explicit financial guidance, focusing instead on governance and dividend discipline. The company maintains a conservative balance sheet with low debt, and promoter holding is a steady 74.5%, according to filings tracked by Inve.money.
Longer-term growth hinges on new capacity. Reports from Arthneeti.com indicate plans to add manufacturing units (P-10 and P-11) for organic chemicals, aiming to support product diversification and import substitution. However, a clear timeline or capex figure has not been disclosed.
Key Points
- Yearly revenue grew 22%, but quarterly profit fell 31%, highlighting volatile earnings.
- The net profit margin dropped 500 bps QoQ as a one-off inventory benefit from Q1 normalized.
- Management offers no formal growth or margin targets, maintaining a conservative, dividend-focused stance.
- Future growth is linked to new capacity for organic chemicals, though details on timing and investment remain scarce.
Hexa Perspective
Chemcon's quarter illustrates the gap between structural positioning and quarterly execution. Its leadership in niche pharmaceutical chemicals is intact, but profits are proving hard to predict from one quarter to the next. The return to a margin in the low teens aligns more closely with its trailing twelve-month average of 11.3%.
Investors are left weighing a stable, cash-generative business with a strong market position against inconsistent quarterly profitability and a lack of strategic clarity on expansion. The stock's premium valuation—trading at a P/E of 44.1 against an industry average of 36.9—prices in its niche leadership but leaves little room for operational stumbles.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.